ClinicalTrials.gov ID NCT05309616 Sponsor Yale University Information provided by Yale University (Responsible Party) Last Update Posted 2025-02-25 Brief Summary The purpose of this phase 2 study is to examine if inhibiting IL-17A activation using the biologic drug Taltz, in idiopathic subglottic stenosis patients will decrease scar fibroblast proliferation therefore reducing [READ MORE]
ClinicalTrials.gov ID NCT06713187 Sponsor Sohag University Information provided by khadiga Mahmoud Salem, Sohag University (Responsible Party) Brief Summary Assessment of interleukin 23 in serum of patients with systemic lupus erythematosus related interstial lung disease . Detailed Description for all patients detailed history taken clinical and rhumatological examination will be assessed [READ MORE]
ClinicalTrials.gov ID NCT05035862 Sponsor Emory University Information provided by Edwin Horwitz, Emory University (Responsible Party) Brief Summary This study is a two strata, dose escalation Phase I clinical trial designed to assess the safety and determine the maximal tolerated dose (MTD) of allogenic cord tissue derived MSCs (cMSCs, stratum 1) [READ MORE]
ClinicalTrials.gov ID NCT06371235 Sponsor CerbaXpert Information provided by CerbaXpert (Responsible Party) Brief Summary The main objective of the study is to evaluate the frequency of placental transfer of self-Ab directed against the mother’s IFN alpha in the newborn, in all women suffering from a pathology frequently associated with the presence [READ MORE]
ClinicalTrials.gov ID NCT05653193 Sponsor Manchester University NHS Foundation Trust Information provided by Manchester University NHS Foundation Trust (Responsible Party) Brief Summary This study explores the role of treatment with interferon-gamma to improve outcomes in chronic pulmonary aspergillosis (CPA). CPA is a progressive infection caused by the fungus Aspergillus affecting patients [READ MORE]
ClinicalTrials.gov ID NCT06130579 Sponsor Peking University People’s Hospital Information provided by Xiao-Jun Huang, Peking University People’s Hospital (Responsible Party) Brief Summary To investigate the efficacy of interferon-α prophylaxis in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with TP53 mutation who were negative for minimal residual disease (MRD) [READ MORE]
ClinicalTrials.gov ID NCT06586710 Sponsor Meyer Children’s Hospital IRCCS Information provided by Carmela Errichiello, Meyer Children’s Hospital IRCCS (Responsible Party) Brief Summary Pediatric SLE includes monogenic forms, some of which involve the interferon type I (IFN-I) pathway. The IFN-I pathway is renally active in adult SLE and correlates with the extent [READ MORE]
ClinicalTrials.gov ID NCT05941845 Sponsor Centre Hospitalier Universitaire de Nice Information provided by Centre Hospitalier Universitaire de Nice (Responsible Party) Study Overview – Brief Summary Membranous Nephropathy (MN) is a renal autoimmune disease mediated by autoantibodies. Current management is based on the use of immunosuppressive therapies. MN patients with a pro-inflammatory Th17 [READ MORE]
ClinicalTrials.gov ID NCT05870475 Sponsor Institute of Hematology & Blood Diseases Hospital, China Information provided by Institute of Hematology & Blood Diseases Hospital, China (Responsible Party) Study Overview – Brief Summary Study purpose: To compare the efficacy and safety of pegylated interferon α-2b in combination with ruxolitinib versus pegylated interferon α-2b alone [READ MORE]
ClinicalTrials.gov ID NCT05843786 Sponsor Hospices Civils de Lyon Information provided by Hospices Civils de Lyon (Responsible Party) Study Overview – Brief Summary Clinical presentation of patients after severe injury such as a severe infection, trauma or extensive burns is characterized by the simultaneous occurrence of dysregulation of the initial inflammatory response [READ MORE]
International Cytokine & Interferon Society, Copyright 2024 Website Design by Rhema Association Management | Privacy Policy
